CN108003150A - The preparation method and applications of 4- heteroaryl qualone derivatives - Google Patents
The preparation method and applications of 4- heteroaryl qualone derivatives Download PDFInfo
- Publication number
- CN108003150A CN108003150A CN201610928440.2A CN201610928440A CN108003150A CN 108003150 A CN108003150 A CN 108003150A CN 201610928440 A CN201610928440 A CN 201610928440A CN 108003150 A CN108003150 A CN 108003150A
- Authority
- CN
- China
- Prior art keywords
- preparation
- qualone
- heteroaryls
- heteroaryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KPCRTHKQZHLYOO-SDNWHVSQSA-N Cc1ccccc1/C(/c1nc(cccc2)c2[o]1)=C\C(NC)=O Chemical compound Cc1ccccc1/C(/c1nc(cccc2)c2[o]1)=C\C(NC)=O KPCRTHKQZHLYOO-SDNWHVSQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
The invention belongs to medicinal chemistry art, it is related to a kind of 4 heteroaryl qualone derivatives and its preparation method and application, the present invention utilizes 4 trifluoromethanesulfonic acid ester group quinolinones under the catalysis of palladium trifluoroacetate and benzothiazole, thiazole, benzoxazoles, the heterocyclic compounds such as oxazole, benzimidazole occur coupling reaction and obtain such as lower structure
Description
Technical field
The present invention relates to medicinal chemistry art, and in particular to a kind of 4- heteroaryls qualone derivative and preparation method thereof,
And application of such compound as a new class of antitumor drug lead compound.
Background technology
Two or more medicines structure is connected into split in a molecule by using principle of hybridization, is formed new
Complex or hybrid molecule, the complex newly formed can have the property of the two concurrently, strengthen pharmacological action, reduce respective poison
Side effect.Split medicine can be acted on the different loci of not isoacceptor or same acceptor, or with multiple and different enzyme effects so that
Reduce the generation of drug resistance.Using the medicine or pharmacophoric group split new drug of known curative effect, it is not difficult to predict split and
New drug pharmacological activity so that new drug development has certain basis, so as to shorten the R＆D process of new drug.Principle of hybridization is
Through being applied successfully in the synthesis of multi-medicament.
Quinolinone is widely present among a variety of biological base molecules with notable biological activity, is widely used in medicine
Learn, as anticancer (Lirbigs Ann 1995,1895-1998), anti-virus and drug for hypertension
(J.Med.Chem.2004,47,5912-5922；J.Med.Chem.2004,47,5923-5936).In addition, quinolinone is organic
It is also a kind of important intermediate in synthesis, because it can easily be converted into 2- chlorine and 2- amino substituted chinoline derivatives.
Therefore chemist is continually striving to develop the new compound based on quinolinone skeleton and brand-new synthetic method.Benzothiazole/evil
Zole derivatives in terms of drug development and pharmacological research have antibacterial, antiallergy, anti-inflammatory, antitumor, anticonvulsion, immunological regulation and
Protect the various active such as nervous system, benzothiazole medicine Riluzole (riluzole) be uniquely launch so far it is effective
The medicine of anti-ALS (amyotrophic lateral sclerosis).Numerous scientific workers are antitumor around benzothiazole
Many work have been done in research, for example, Nottingham, GBR institute of oncology finds a series of antitumor benzothiazole derivant, its
Middle 2- (4- aminophenyls) benzothiazoles (CJM-126) have come into clinical test, which has breast cancer cell
There is high selection cytotoxicity.Giuseppe Trapani etc. have studied the analog of CJM-126, and design synthesizes
Imidazobenzothiazole equally has preferable antitumous effect, and the change is found in further live test
Compound has good intestinal absorption effect.
In recent years, scientists had gradually had the bis-heterocyclic compounds of quinolinone skeleton using principle of hybridization synthesis, its
In some compounds there is special physiological activity, such as acceptor inhibitor, antagonist, active anticancer
(Bioorg.Med.Chem.Lett.,2010,20,7414-7420；J.Med.Chem.,2009,52,278-292).But utilize
The quinolinone of multi-biological activity and benzothiazole, benzoxazoles isoreactivity fragment are carried out split, synthesis by medicine principle of hybridization
New 4- heteroaryl qualone derivatives, have no that pertinent literature is reported, new 4- heteroaryl qualone derivatives pair at present
New type antineoplastic medicine is studied, develops one's own intellectual property and is of great significance.
The content of the invention
The object of the present invention is to provide a kind of 4- heteroaryls qualone derivative and preparation method thereof, and such compound
Application as a new class of antitumor drug lead compound.
The purpose of the present invention is what is be achieved through the following technical solutions：
The present invention is from 4- trifluoromethanesulfonic acid ester group quinolinones simple and easy to get, there is provided synthesis obtains 4- heteroaryl quinolines
Quinoline ketone derivatives, such compound have following structural formula,
Wherein, R1, R2For different the position of substitution, alkyl, aryl, alkoxy, aryloxy group, halogen, the fluoroform of different numbers
One kind of base, R is hydrogen, methyl, ethyl, at least one of benzyl, and Y is sulphur, oxygen, at least one of nitrogen-atoms.
In general formula preferably：R1, R2For the alkyl of the mono-substituted C1-C5 of diverse location, alkoxy, halogen, trifluoromethyl or
Polysubstituted halogen.
The preparation method of the 4- heteroaryls qualone derivative is as follows：
In organic solvent, addition 4- trifluoromethanesulfonic acid ester group quinolinones and benzothiazole, thiazole, benzoxazoles, oxazole,
The heterocyclic compounds such as benzimidazole react under the action of catalyst, and reaction temperature is at 80 DEG C -120 DEG C, time 10-20
Hour, obtain target product.
Catalyst used is palladium trifluoroacetate, palladium sulfate, one kind in two triphenylphosphine palladium acetates, preferably trifluoroacetic acid
Palladium.Ligand used is PCy3, PPh3, one kind in Xantphos, preferably PCy3, alkali used is K2CO3, Cs2CO3, K3PO4In
One kind, preferably K2CO3。
Organic solvent is dimethylbenzene, one kind in chlorobenzene, dioxane, preferably dimethylbenzene, raw material 4- triflates
The dispensing of base quinolinone and solvent is than for 0.1~0.5 mM every milliliter.
In terms of raw material proportioning, the molar ratio of the heterocyclic compound such as 4- trifluoromethanesulfonic acid ester group quinolinones and benzothiazole is
1:2~1:4.
The mass ratio that the addition of catalyst accounts for reaction raw materials is 2.5~10%.
Using the 4- heteroaryls qualone derivative of the present invention as active ingredient, available for being prepared into anti esophageal cancer, forefront
Gland cancer, liver-cancer medicine.Through preliminary test, 4- heteroaryl qualone derivatives prepared by the present invention show kinds of tumor cells
Antitumor activity, can be as the candidate or lead compound that further develop, applied to preparing cancer therapy drug.
Embodiment
The embodiment of the present invention is described in detail, it is necessary to explains below, it is described herein specifically
Embodiment is merely to illustrate and explain the present invention, and is not intended to limit the invention.
On the one hand, the object of the present invention is to provide synthesize a kind of 4- heteroaryls qualone derivative, it is characterised in that such
Compound has structure as shown below,
Wherein R1, R2For in different the position of substitution, the alkyl of different numbers, aryl, alkoxy, aryloxy group, halogen, trifluoromethyl
At least one, R for hydrogen, methyl, ethyl, at least one of benzyl, Y for sulphur, oxygen, at least one of nitrogen-atoms.
In the present invention, alkyl is preferably the alkyl of C1-C5, and alkoxy is preferably the alkoxy of C1-C5, and aryloxy group is preferably
The aryloxy group of C6-C10.
4- heteroaryls qualone derivative of the present invention is more preferably R1For methyl, methoxyl group, R is methyl,
Ethyl is shown below：
On the other hand, process provides a kind of method of convenient synthesis 4- heteroaryl qualone derivatives.Including：
1st, in organic solvent, 4- trifluoromethanesulfonic acid ester group quinolinones and benzothiazole, thiazole, benzoxazoles, oxazole, benzene are added
And the heterocyclic compound such as imidazoles reacts under the action of palladium trifluoroacetate, 4- heteroaryl qualone derivatives are obtained.
2nd, in the method for the present invention, step 1 using palladium sulfate, two triphenylphosphine palladium acetates except using palladium trifluoroacetate, can also be obtained
To product, but yield is relatively low.Ligand removes and uses PCy3, use PPh3, Xantphos also can obtain product, but yield is relatively low.It is used
Alkali is K2CO3, use Cs2CO3, K3PO4Also product is can obtain, but yield is relatively low.Solvent uses chlorobenzene, two except dimethylbenzene is used
Six ring of oxygen also can obtain product, but yield is relatively low.
3rd, in the method for the present invention, step 1 reaction condition includes, 80 DEG C -120 DEG C of temperature, when the time is 10-20 small；Products therefrom
Net product is obtained through the purification such as column chromatography or recrystallization；Recrystallization solvent for use is acetone, in ethanol, methanol, ethyl acetate
One kind or two of which mixture.
Another further aspect, the present invention provides such as above-mentioned 4- heteroaryls qualone derivative, antitumor activity evaluation test is tied in vitro
Fruit, wherein compound 2 and 5 pair liver cancer inhibited for PC3 prostate cancers, the EC109 cancer of the esophagus, SMMC7721 liver cancer
Antitumor activity be substantially better than 5-fluor-uracil, can be as the candidate or lead compound further developed, applied to system
Standby antitumor drug.
Method is exemplified below：
Prepare following compound：
1 4- benzothiazolyl-N- Methyl-quinoline ketone of compound
4- trifluoromethanesulfonic acid ester group quinolinones (76.7mg, 0.25mmol), benzothiazole (101mg, 0.75mmol), Pd (TFA)2
(4.1mg, 0.0125mmol), PCy3(14mg, 0.05mmol) CuI (4.7mg, 0.025mmol) and 1mL dimethylbenzene are in 5mL's
When 140 DEG C of stirring reactions 12 are small in reaction tube, 20mL ethyl acetate is then added, is eaten successively using saturated sodium bicarbonate, saturation
Salt water washing, anhydrous sodium sulfate drying.Concentration, column chromatography (ethyl acetate/petroleum ether=1:4) faint yellow solid is obtained
61.3mg, total recovery 84%.1H NMR(400MHz,CDCl3) δ 3.81 (s, 3H), 7.17 (s, 1H), 7.34 (t, J=8.0Hz,
1H), 7.47 (d, J=8.4Hz, 1H), 7.52 (t, J=8.0Hz, 1H), 7.60 (td, J=0.8,8.0Hz, 1H), 7.66 (td,
J=1.2,8.4Hz, 1H), 8.00 (d, J=8.0Hz, 1H), 8.21 (d, J=8.4Hz, 1H), 8.65 (dd, J=0.8,
8.0Hz,1H).13C NMR(100MHz,CDCl3)29.9,114.7,118.4,121.8,122.9,124.1,124.2,126.4,
126.9,128.2,131.6,135.2,140.7,141.6,154.1,161.4,163.9.HRMS for C17H13N2OS+(M++
H):calcd.293.0749,found 293.0750
2 4- benzothiazolyls -6- methoxy-. N-methyls of compound-quinolinone
Synthetic method is the same as compound 1, yellow solid, yield 76%.1H NMR(500MHz,CDCl3)δ3.79(s,3H),3.86
(s, 3H), 7.20 (s, 1H), 7.27 (dd, J=3.0,9.5Hz, 1H), 7.39 (d, J=9.5Hz, 1H), 7.51 (t, J=
7.5Hz, 1H), 7.58 (t, J=7.5Hz, 1H), 7.99 (d, J=8.0Hz, 1H), 8.19 (d, J=8.5Hz, 1H), 8.30 (d,
J=3.0Hz, 1H)13C NMR(125MHz,CDCl3)δ30.0,55.8,110.3,115.9,119.1,120.1,121.8,
124.2,124.7,126.5,126.9,135.1,135.3,140.7,154.1,155.3,161.0,164.2.HRMS for
C18H15N2O2S+(M++H):calcd.323.0854,found 323.0854
3 4- benzothiazolyls -6- chloro-n-methyls of compound-quinolinone
Synthetic method is the same as compound 1, yellow solid, yield 83%.1H NMR(500MHz,CDCl3)δ3.78(s,3H),7.20
(s, 1H), 7.39 (d, J=9.0Hz, 1H), 7.52 (t, J=7.5Hz, 1H), 7.58-7.62 (m, 2H), 7.99 (d, J=
8.0Hz, 1H), 8.23 (d, J=8.0Hz, 1H), 8.76 (d, J=2.0Hz, 1H)13C NMR(125MHz,CDCl3)δ30.1,
116.0,119.4,121.8,124.5,125.2,126.7,127.0,127.7,128.8,131.6,135.1,139.3,
140.4,154.1,161.0,163.3.HRMS for C17H12ClN2OS+(M++H):calcd.327.0359,
found327.0356
The 4 fluoro- N- Methyl-quinolines ketone of 4- benzothiazolyls -6- of compound
Synthetic method is the same as compound 1, yellow solid, yield 51%.1H NMR(500MHz,CDCl3)δ3.80(s,3H),7.25
(s, 1H), 7.40-7.44 (m, 2H), 7.52 (t, J=7.5Hz, 1H), 7.60 (t, J=8.0Hz, 1H), 7.99 (d, J=
8.0Hz, 1H), 8.22 (d, J=8.0Hz, 1H), 8.59 (dd, J=3.0,10.0Hz, 1H)13C NMR(125MHz,CDCl3)δ
30.2,113.9 (d, JF=25Hz), 116.1 (d, JF=24.9Hz), 119.3,113.3 (d, JF=23.8Hz), 121.8,
(124.4,125.3,126.7,127.0,135.0,137.3,140.4 d, JF=2.6Hz), 154.1,158.4 (d, JF=
241.9Hz),161.1,163.6.19F NMR(376MHz,CDCl3)δ-119.3.HRMS for C17H12FN2OS+(M++H):
calcd.311.0654,found 311.0656
5 4- benzothiazolyls -6- methyl-N ethyls of compound-quinolinone
Synthetic method is the same as compound 1, yellow solid, yield 54%.1H NMR(500MHz,CDCl3) δ 1.41 (t, J=7.5Hz,
3H), 2.42 (s, 3H), 4.43 (q, J=7.5Hz, 2H), 7.10 (s, 1H), 7.38 (d, J=8.5Hz, 1H), 7.46 (d, J=
8.5Hz, 1H), 7.50 (t, J=8.0Hz, 1H), 7.59 (t, J=8.5Hz, 1H), 7.99 (d, J=8.0Hz, 1H), 8.22 (d,
J=8.0Hz, 1H), 8.32 (s, 1H)13C NMR(125MHz,CDCl3)δ12.9,21.0,37.7,114.5,118.6,
121.8,124.2,126.3,126.8,127.8,132.3,132.8,135.3,137.7,141.4,154.1,160.7,
164.1.HRMS for C19H17N2OS+(M++H):calcd.321.1062,found 321.1061
6 4- of compound (5- bromines) benzothiazolyl-N- Methyl-quinoline ketone
Synthetic method is the same as compound 1, yellow solid, yield 39%.1H NMR(500MHz,CDCl3)δ3.81(s,3H),7.16
(s, 1H), 7.33 (t, J=8.0Hz, 1H), 7.47 (d, J=8.5Hz, 1H), 7.63-7.68 (m, 2H), 7.85 (d, J=
8.5Hz, 1H), 8.36 (d, J=1.5Hz, 1H), 8.61 (d, J=9.0Hz, 1H)13C NMR(125MHz,CDCl3)δ30.0,
114.7,118.2,120.5,122.8,123.0,124.3,127.1,128.0,129.6,131.7,134.0,140.7,
141.1,155.2,161.3,165.7.HRMS for C17H12BrN2OS+(M++H):calcd.370.9854,found
370.9851
74 thiazolyl-N- Methyl-quinoline ketone of compound
Synthetic method is the same as compound 1, yellow solid, yield 85%.1H NMR(500MHz,CDCl3)δ3.78(s,3H),6.84
(s, 1H), 7.27 (d, J=8.0Hz, 1H), 7.46 (d, J=8.5Hz, 1H), 7.65 (t, J=8.0Hz, 1H), 7.79 (d, J=
8.0Hz,1H),8.07(s,1H),8.98(s,1H). 13C NMR(125MHz,CDCl3)δ29.7,114.8,119.9,122.6,
123.3,126.9,131.5,132.6,140.2,140.4,143.5,154.4,161.3.HRMS for C13H11N2OS+(M++
H):calcd.243.0592,found 243.0590
8 4- benzoxazolyl-N- Methyl-quinoline ketone of compound
Synthetic method is the same as compound 1, yellow solid, yield 81%.1H NMR(500MHz,CDCl3)δ3.80(s,3H),7.38–
7.48 (m, 4H), 7.62-7.68 (m, 3H), 7.89 (d, J=7.5Hz, 1H), 9.27 (d, J=8.0Hz, 1H)13C NMR
(125MHz,CDCl3)δ29.9,111.1,114.6,117.6,121.1,123.0,124.1,125.2,126.8,128.3,
131.4,134.3,140.7,142.0,150.2,159.4,161.4.HRMS for C17H13N2O2 +(M++H):
calcd.277.0977,found 277.0978
9 4- oxazolyl-N- Methyl-quinoline ketone of compound
Synthetic method is the same as compound 1, yellow solid, yield 65%.1H NMR(500MHz,CDCl3)δ3.78(s,3H),7.02
(s, 1H), 7.32 (t, J=7.5Hz, 1H), 7.46 (d, J=8.5Hz, 1H), 7.58 (s, 1H), 7.66 (t, J=7.5Hz,
1H), 8.02 (d, J=8.0Hz, 1H), 8.10 (s, 1H)13C NMR(125MHz,CDCl3)δ29.8,115.0,117.8,
120.7,122.7,126.4,127.8,131.4,135.8,140.6,147.6,152.1,161.6.HRMS for C13H11N2O2 +(M++H):calcd.227.0821,found 227.0820,for C13H10N2NaO2 +(M++Na):calcd.249.0640,
found 249.0645
10 4- benzimidazolyl-N- Methyl-quinoline ketone of compound
Synthetic method is the same as compound 1, yellow solid, yield 65%.1H NMR(500MHz,CDCl3)δ3.75(s,3H),3.82
(s, 3H), 6.90 (s, 1H), 7.22 (t, J=8.0Hz, 1H), 7.37-7.43 (m, 2H), 7.47-7.48 (m, 2H), 7.62-
7.65 (m, 2H), 7.89 (d, J=7.5Hz, 1H)13C NMR(125MHz,CDCl3)δ29.8,31.3,110.0,114.7,
119.7,120.5,122.9,123.0,123.7,124.1,127.7,131.6,135.9,139.4,140.5,143.1,
148.9,161.2.HRMS for C18H16N3O+(M++H):calcd.290.1293,found 290.1291
Test case
Choose compound 1-10 obtained above and carry out following determination of activity.
Experiment material:
1 man―machine systems：It is purchased from Chinese Academy of Sciences's Shanghai cell bank.
2 test medicines：After being dissolved with DMSO, 10000 micrograms per millilitre initial concentrations are configured to, it is spare.
3 0.9% physiological saline：Lot number 201521112, specification 250mL：2.25g, Zhengzhou Yonghe Pharmaceutical Co's product.
45 FU 5 fluorouracil parenteral solutions (5-Fu), lot number 140107, specification 10mL：0.25g/ branch, the general medicine company in the rising sun East Sea, Shanghai have
Limit Products.
Experimental method:
Cell routine is inoculated in complete medium, through 37 DEG C, 5% CO2Saturated humidity culture, amplification.Cell is with 0.25%
After Trypsin Induced, adding nutrient solution to be diluted to 1 × 105/mL tumor cell suspensions, (tire expects blue dyeing, the equal ＞ of viable count
95%), it is for experiment.It is dense in setting negative control hole and Positive control wells, test sample various concentrations hole on 96 hole sterile culture plates
Degree is set as 64,32,16,8,4,2,1,0.5 micrograms per millilitre, while each concentration sets 3 multiple holes.The cell prepared is hanged
Liquid is inoculated in 96 hole sterile culture plates, cultivates the compound of addition various concentrations after 24h.The training of equivalent is added in negative control hole
Nutrient solution, inserts in incubator and cultivates.Taken out after 72h, 20 μ L of MTT added per hole, continued to cultivate 4h, centrifuged after taking-up,
Supernatant is abandoned in suction.DMSO150 μ L are added per hole, concussion is completely dissolved the crystallization of hyacinthine first a ceremonial jade-ladle, used in libation.The OD in each hole is measured with microplate reader
Value, its IC is calculated by SPSS50。
Experimental result
Antitumor activity evaluation data of the above-claimed cpd to three-type-person's class tumour cell：
Test result indicates that：Compound 2,5 shows preferable antitumor activity, the suppression to SMMC7721 liver cancer cells
Activity is better than 5-fluor-uracil, can be as the candidate or lead compound further developed, applied to preparing cancer therapy drug.
Claims (8)
1. a kind of 4- heteroaryls qualone derivative, it is characterised in that the 4- heteroaryls qualone derivative has following knot
Structure,
Wherein, R1, R2For different the position of substitution, the alkyl of different number, aryl, alkoxy, aryloxy group, halogen, trifluoromethyl
One kind, R is hydrogen, methyl, ethyl, at least one of benzyl, and Y is sulphur, oxygen, at least one of nitrogen-atoms.
2. 4- heteroaryls qualone derivative as claimed in claim 1, it is characterised in that：R1, R2For the monosubstituted of diverse location
C1-C5 alkoxy, halogen, trifluoromethyl or polysubstituted halogen.
A kind of 3. preparation method of 4- heteroaryl qualone derivatives as claimed in claim 1, it is characterised in that：Target product 4-
The preparation method of heteroaryl qualone derivative is as follows：In organic solvent, 4- trifluoromethanesulfonic acid ester group quinolinones and benzene are added
And thiazole, thiazole, benzoxazoles, oxazole, the heterocyclic compound such as benzimidazole react under the action of catalyst, reaction temperature
Degree when the time is 10-20 small, obtains target product at 80 DEG C -120 DEG C.
4. preparation method used according to claim 3, it is characterised in that：The catalyst is palladium trifluoroacetate, sulphur
Sour palladium, one kind in two triphenylphosphine palladium acetates, preferably palladium trifluoroacetate, ligand used are PCy3, PPh3, in Xantphos
One kind, preferably PCy3, alkali used is K2CO3, Cs2CO3, K3PO4In one kind, preferably K2CO3。
5. preparation method used according to claim 3, it is characterised in that：The organic solvent for dimethylbenzene, chlorobenzene,
One kind in dioxane, preferably dimethylbenzene, the dispensing of raw material 4- trifluoromethanesulfonic acid ester group quinolinones and solvent compares for 0.1~
0.5 mM every milliliter.
6. preparation method used according to claim 3, it is characterised in that：4- trifluoromethanesulfonic acid ester group quinolinones and benzene
And the molar ratio of the heterocyclic compound such as thiazole is 1:2~1:4.
7. according to the preparation method used of claim 3 or 4, it is characterised in that：It is former that the addition of catalyst accounts for reaction
The amount of substance ratio of material is 2.5~10%.
8. application of the 4- heteroaryls qualone derivative as claimed in claim 1 in cancer therapy drug is prepared, it is characterised in that：
Using 4- heteroaryls qualone derivative as active ingredient, available for being prepared into anti esophageal cancer, prostate cancer, liver-cancer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610928440.2A CN108003150A (en) | 2016-10-31 | 2016-10-31 | The preparation method and applications of 4- heteroaryl qualone derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610928440.2A CN108003150A (en) | 2016-10-31 | 2016-10-31 | The preparation method and applications of 4- heteroaryl qualone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108003150A true CN108003150A (en) | 2018-05-08 |
Family
ID=62047179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610928440.2A Pending CN108003150A (en) | 2016-10-31 | 2016-10-31 | The preparation method and applications of 4- heteroaryl qualone derivatives |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108003150A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115286572A (en) * | 2022-07-15 | 2022-11-04 | 绍兴文理学院 | 4-acyl-isoquinoline derivative and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1340051A (en) * | 1999-02-11 | 2002-03-13 | 辉瑞产品公司 | Heteroaryl-substituted quinoline-2-one derivatives useful asticancer agents |
| WO2002024687A1 (en) * | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
| CN1659165A (en) * | 2002-04-05 | 2005-08-24 | 希龙公司 | Quinolinone derivatives |
| KR100744826B1 (en) * | 2006-04-05 | 2007-08-01 | 한국화학연구원 | Quinolinone derivatives substituted with imidazole group |
| EP1900732A1 (en) * | 2005-06-24 | 2008-03-19 | Toyama Chemical Co., Ltd. | Novel nitrogenated heterocyclic compound and salt thereof |
| CN104557696A (en) * | 2015-01-21 | 2015-04-29 | 重庆工商大学 | Method for synthesizing 4-polyfluoroaryl-substituted quinolinone compounds |
| CN104817535A (en) * | 2015-03-19 | 2015-08-05 | 广西师范大学 | Quinolinone derivative, and synthetic method and application thereof |
| CN105622574A (en) * | 2016-02-04 | 2016-06-01 | 桂林师范高等专科学校 | 3-benzimidazole-2(1H)-quinolinone derivative and preparation method and application thereof |
-
2016
- 2016-10-31 CN CN201610928440.2A patent/CN108003150A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1340051A (en) * | 1999-02-11 | 2002-03-13 | 辉瑞产品公司 | Heteroaryl-substituted quinoline-2-one derivatives useful asticancer agents |
| WO2002024687A1 (en) * | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
| CN1659165A (en) * | 2002-04-05 | 2005-08-24 | 希龙公司 | Quinolinone derivatives |
| EP1900732A1 (en) * | 2005-06-24 | 2008-03-19 | Toyama Chemical Co., Ltd. | Novel nitrogenated heterocyclic compound and salt thereof |
| KR100744826B1 (en) * | 2006-04-05 | 2007-08-01 | 한국화학연구원 | Quinolinone derivatives substituted with imidazole group |
| CN104557696A (en) * | 2015-01-21 | 2015-04-29 | 重庆工商大学 | Method for synthesizing 4-polyfluoroaryl-substituted quinolinone compounds |
| CN104817535A (en) * | 2015-03-19 | 2015-08-05 | 广西师范大学 | Quinolinone derivative, and synthetic method and application thereof |
| CN105622574A (en) * | 2016-02-04 | 2016-06-01 | 桂林师范高等专科学校 | 3-benzimidazole-2(1H)-quinolinone derivative and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| SHENG, JIE ET AL.: "Generation of 4-substituted coumarins via C-H bond activation under palladium bromide-copper(I) bromide cooperative catalysis", 《TETRAHEDRON》 * |
| 敬松: "《中国花膳与花疗》", 31 January 2013 * |
| 邱峰: "《天然药物化学》", 30 September 2011 * |
| 麻生明: "《金属参与的现代有机合成反应》", 30 June 2001 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115286572A (en) * | 2022-07-15 | 2022-11-04 | 绍兴文理学院 | 4-acyl-isoquinoline derivative and preparation method and application thereof |
| CN115286572B (en) * | 2022-07-15 | 2023-10-13 | 绍兴文理学院 | 4-acyl-isoquinoline derivative and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6621486B2 (en) | Pyrido-azaheterocyclic compound and production method and use thereof | |
| CN102408403B (en) | Pseudolarix acid derivatives as well as preparation method and application thereof | |
| CN103880822A (en) | 2,4,6-trisubstituted pyrimidine compounds containing 1,2,3-triazole, preparation method and application thereof | |
| CN104725393B (en) | Bergenin derivative as well as preparation method and application thereof | |
| CN105566215A (en) | Preparation method of Stivarga | |
| CN106674242A (en) | Curcumol derivatives with anti-tumor activity, and preparation method and application of curcumol derivatives | |
| CN103992310B (en) | One group replaces benzo heterocyclic amine derivant and preparation method thereof and the related application as IMPDH inhibitor | |
| CN108003150A (en) | The preparation method and applications of 4- heteroaryl qualone derivatives | |
| CN108329232B (en) | Hydrazide derivative and application thereof | |
| CN103864765B (en) | Benzazepine analog derivative containing five-membered ring, Preparation Method And The Use | |
| CN113248518B (en) | Pyrimidine piperazine derivative and preparation method and application thereof | |
| CN105732631A (en) | N9 vinylpurine and synthesis method thereof, and method for synthesizing polysubstituted chiral azacyclonucleoside analogs from N9 vinylpurine | |
| CN106397407B (en) | The preparation method of antitumor drug AZD9291 derivatives | |
| CN106317030B (en) | A kind of 4- indyl coumarin derivative and its preparation method and application | |
| CN104016898A (en) | 3,4-disubstituted pyrrole compound as well as preparation method and application thereof | |
| CN111909053B (en) | Diarylamine unit-based amide derivative and preparation method and application thereof | |
| CN111233843B (en) | Gamma-butenolide derivative and preparation method and application thereof | |
| CN107434781A (en) | A kind of preparation method and applications of 1- alkenyls-isoquinilone derivatives | |
| CN106632374A (en) | Isomannide-bis-benzimidazole salt compounds and preparation method thereof | |
| CN106588749A (en) | Multi-substituted carbazole-type compound, synthesis method, and application thereof | |
| CN106478653B (en) | Mono- imidazole salt compound of isobide-and preparation method thereof | |
| CN108358903B (en) | Synthesis method of 2-substituted heterocyclic quinazolinone compound | |
| CN103435574B (en) | Mercapto benzothiazole substituent acenaphtho-heterocycle compound and application thereof | |
| CN104140415B (en) | Alpha, beta unsaturated ketone compounds containing benzo five-membered unsaturated heterocycle structures as well as preparation method and application of compounds | |
| CN103709146B (en) | One class is containing the quinolin-4-amines derivative of benzimidazole structure, its method for making and medicinal use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180508 |
|
| WD01 | Invention patent application deemed withdrawn after publication |